Polycystic Ovary Syndrome: A Common But Often Unrecognized Condition

Journal of Midwifery and Women's Health

Volumn 57, Issue 3, 2012, Pages 221-230

  Shannon, Maureen ^a   Wang, Yusharn ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Clinical care; Polycystic ovary syndrome; Review

Indexed keywords

ANTIANDROGEN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE;

AMENORRHEA; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FEMALE; GLUCOSE METABOLISM; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MENOPAUSE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SYMPTOMATOLOGY; VAGINA RING;

AMENORRHEA; FEMALE; HUMANS; HYPERANDROGENISM; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME; PREVALENCE; REPRODUCTION;

EID: 84862062147     PISSN: 15269523     EISSN: 15422011     Source Type: Journal    
DOI: 10.1111/j.1542-2011.2012.00161.x     Document Type: Review

References (65)

1. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Polycystic ovary syndrome. Obstet Gynecol. 2009;114(4):936-949.
2. Norman RJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome. Med J Aust. 2004;180(3):132-137.
3. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health. 2011;3:25-35.
4. March WA, Moore VM, Wilson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25:544-541.
5. Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fertil Steril. 2011;95(5):1544-1548.
6. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Oxford : Blackwell Scientific Publications; 1992;1997:377-384.
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Working Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19(1):41-47.
8. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-488.
9. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;112(10):1210-1217.
10. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41-51.
11. Alvarez-Blasco F, Botella-Carretero JJ, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166:2081-2086.
12. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am. 2005;34:677-705.
13. Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:787-796.
14. Kurzrock R, Cohen PR. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. Med Hypotheses. 2007;68:480-483.
15. Vink JM, Sadrzadeh S, Lambalk, CV, Boomsma DI. Heritability of polycystic ovary syndrome (PCOS) in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100-2104.
16. Deligeoroglou E, Kouskouti C, Christopoulos P. The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endogrinol. 2009;25(9):603-609.
17. Kowalska I, Malecki MT, Straczkowski M, et al. The FTO gene modifies weight, fat mass and insulin sensitivity in women with polycystic ovary syndrome, where its role may be larger than in other phenotypes. Diabetes Metab. 2009;35(4):328-331.
18. Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994;79:1328-1333.
19. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278-285.
20. Eisner JR, Barnett MA, Dumesic DA, Abbott DH. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril. 2002;77:167-172.
21. Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Pubertal development in children and adolescents born after IVF and spontaneous conception. Hum Reprod. 2008;12:2791-2798.
22. Cresswell JL, Barker DJP, Osmond C, Egger P, Phillips DIW, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet. 1998;350(9085):1131-1135.
23. Katz VL, Lentz G, Lobo RA, Gershenson D. Comprehensive Gynecology. 5th ed. Philadelphia, PA : Mosby-Elsevier; 2007: 987.
24. Callahan TL, Caughey AB. Obstetrics & Gynecology. 5th ed. Philadelphia, PA : Wolters Kluwer & Lippincott Williams & Wilkins; 2009: 226.
25. Ozdemir S, Ozdemir M, Gorkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89(2):199-204.
26. Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome. Drugs. 2006;66:903-912.
27. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R, Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol. 2011;24:15-20.
28. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997;99(4):505-512.
29. Pasquali R, Casimirri F, Venturoli S, et al. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metab Clin Exp. 1994;43(6):706-713.
30. Yildirim B, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003;79:1358-1364.
31. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;28:882-892.
32. Ovalle F, Azziz R. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2002;77:1095-1105.
33. McGowan MP. Polycystic ovary syndrome: a common endocrine disorder and risk factor for vascular disease. Curr Treat Options Cardiovasc Med. Epub 2011 May 12.
34. Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril. 2011;95:210-215.
35. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800.
36. Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann NY Acad Sci. 2006;1092:158-174.
37. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(3):1017-1023.
38. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathw Cardiol. 2005;4(4):198-203.
39. Carmina E. Metabolic syndrome in polycystic ovary syndrome. Minerva Ginocol. 2011;58(2):109-114.
40. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Meta. 2005;90(4):1929-1935.
41. Hart R, Doherty DA, Mori T, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril. 2011;95(7):2347-2353.
42. Wiltgen D, Spritzer Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94:2493-2496.
43. Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673-683.
44. Puurunen J, Piltonen T, Morin-Papunen, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011; 96(6):1827-1834.
45. Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011;93(3):623-632.
46. Schmidt J, Brannstrom M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrin Metab. 2011;96(7):1-8.
47. De Franca Neto AH, Rogatto S, Amorim MM, Tamanaha S, Aoki T, Aldrighi JM. Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrino. 2010;26(10):701-711.
48. Fearnley EJ, Marquart L, Spurdle AB, et al. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010;21:2303-2308.
49. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009;19(3):398-405.
50. Nitsche K, Ehrmnn DA. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2010;24:717-730.
51. Tasali E, van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin. 2008;3(1):37-46.
52. Ayas NT, White DP, Al-Delaimy WK, et al. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care. 2003;26:380-384.
53. Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep time with diabetes mellitus and impaired glucose intolerance. Arch Intern Med. 2005;165:863-867.
54. Patel SR, Ayas NT, Malhotra MR, et al. A prospective study of sleep duration and mortality risk in women. Sleep. 2004;27:440-444.
55. Jordan AS, McEvoy RD. Gender differences in sleep apnea: epidemiology, clinical presentation and pathogenic mechanisms. Sleep Med Rev. 2003;7:377-389.
56. Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med. 2001;163:608-613.
57. Young T, Finn L, Austin D, et al. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med. 2003;167(9):1181-1185.
58. Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001;86(2):517-520.
59. Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86(3):1175-1180.
60. Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome. Obset Gynecol. 2011;117(1):145-152.
61. Rassi A, Veras AB, dos Reis M, et al. A prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry. 2010;51(6):599-602.
62. Rosenfield RL. What every physician should know about polycystic ovary syndrome. Dermatol Ther. 2008;21:354-361.
63. Battaglia C, Mancini F, Fabbri R, et al. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. Fertil Steril. 2010;94:1417-1425.
64. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-522.
65. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol. 2008;111:959-968.